October 2014 Br J Cardiol 2014;21:146 Online First
Drs Usha Rao and Simon C Eccleshall
Dear Sirs, Ischaemic heart disease (IHD) is a major cause of mortality and morbidity, and percutaneous coronary intervention (PCI) is a mainstay of treatment. The management of IHD has been revolutionised by major advancements in the field of coronary angioplasty, starting with the use of balloons for percutaneous transluminal coronary angioplasty (PTCA) in 1977 by Gruentzig.1 However, their use was limited by acute recoil (approximately 40%), vessel dissection and a high re-stenosis rate (50%). To treat the acute problems of recoil and dissection (with acute vessel closure) and reduce the rate of re-stenosis, coronary stents were introduced
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits